CD274 and neoplasm: In a clinical trial, Li et al. reported that a TGF-β receptor (TGF-βR) inhibitor enhanced tumor-infiltrating T cells, and significantly sensitized metastatic CRC to KN046, a drug that blocks PD-L1 and cytotoxic T-lymphocyte-associated protein 4, by targeting the formation of CAFs.